<DOC>
	<DOCNO>NCT02081027</DOCNO>
	<brief_summary>Determine riluzole show evidence efficacy , safety , tolerability target drug-refractory irritability ( DRI ) person autism spectrum disorder ( ASD ) .</brief_summary>
	<brief_title>Pilot Study Riluzole Drug-Refractory Irritability Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Age ≥ 12 &lt; 26 year . Weight great 50 kg . Diagnosis ASD Drugrefractory irritability , define screen ABC Irritability subscale ( ABCI ) score ≥18 AND 1 ) failure clinically adequate treatment trial aripiprazole risperidone 2 ) failure least three previous clinically adequate drug trial target irritability ( one trial must include aripiprazole risperidone ) , confirm caregiver report medical record review available . Stable dose concomitant psychotropic medication ( include target irritability ) four week prior screen visit study . Presence parent/guardian willing serve informant behavioral outcome measure ship control sample Extracellular SignalRelated Kinase biomarker ( ERK ) assay . Current use two concomitant psychotropic drug target irritability . Current use valproic acid . Current use drug know interaction riluzole Current use drug concomitant glutamatergic glutamatergic modulate action medication . For female subject child bear potential , positive serum pregnancy test . History pancreatitis . Hemoglobin le equal 8.0 gm/dL . Neutropenia absolute neutrophil count less equal 1.0 K/mcL . Problems kidney function , assess lab work Any major chronic medical chronic respiratory illness consider uncontrolled Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>